Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New approach for potential treatment of liver cancer patients with Hep B virus infection

Researchers from Duke-NUS Medical School, Singapore General Hospital (SGH) and Lion TCR have demonstrated that they were able to engineer HBV-specific T cells, a type of immune cells found in the body, to treat Hepatocellular carcinoma (HCC), a commonly occurring liver cancer.

The treatment was also individualised, as T cells that were engineered were specific to the patients.

The approach was successfully performed on two liver transplanted patients who had HBV associated liver cancer recurrence with one patient seeing a reduction in size of the tumour lesions.

Findings are published in the journal Gastroenterology.

Chronic hepatitis B virus (HBV) infection is predominant in Asia and is highly associated with the development of Hepatocellular carcinoma (HCC), the commonly occurring liver cancer.

The currently effective treatments for small to moderate size HCC are restricted to surgery, liver transplantation and loco-regional treatment that kill cancer cells by interventional radiologic means, while treatment with drugs helps only in a modest increase in the overall survival in more extensive disease.

In patients who have HCC recurrence after liver transplantation, the treatment options are even more limited.

"In this study we showed that the integrated HBV-DNA gene components in the HCC cells were able to activate functional HBV-specific T cells. Hence, by analysing the specific HBV- DNA integration patterns in these HCC cells, we were able to select, design and engineer the individualised T cells for therapy. Our studies showed that these engineered T cells were able to destroy the tumour," said Dr Antonio Bertoletti, Professor of the Emerging Infectious Diseases (EID) Programme at Duke-NUS, Founder of the Singapore biotech company Lion TCR and co- author of the study.

"There were over 20 T cell infusions that were successfully performed on the two liver- transplanted patients. None of the patients experienced adverse reactions related to the treatment and one of them had a reduction in the tumour size of distant metastases of the liver cancer. Given that 80 per cent of the HCC cases in Asia are currently HBV-related, this approach could lead to a major breakthrough in improving the survival and quality of life of patients suffering from this disease," said Dr Thinesh Lee Krishnamoorthy, Consultant, Department of Gastroenterology and Hepatology, SGH, and co-author of this study.

The authors plan to further refine the technique and treatment strategy with further research study and trials to improve the efficacy of the therapy.

Source: Duke-NUS Medical School

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation